KR102073034B1 - 항cxcr3 항체 - Google Patents

항cxcr3 항체 Download PDF

Info

Publication number
KR102073034B1
KR102073034B1 KR1020147023225A KR20147023225A KR102073034B1 KR 102073034 B1 KR102073034 B1 KR 102073034B1 KR 1020147023225 A KR1020147023225 A KR 1020147023225A KR 20147023225 A KR20147023225 A KR 20147023225A KR 102073034 B1 KR102073034 B1 KR 102073034B1
Authority
KR
South Korea
Prior art keywords
antibody
cxcr3
amino acid
seq
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020147023225A
Other languages
English (en)
Korean (ko)
Other versions
KR20140116525A (ko
Inventor
미쉘 유드
제니퍼 테드스톤
트래이시 로디
카렌 비. 카터
티모씨 디. 코너스
제이슨 로버트 핀크니
엘리자베쓰 매스터존
류윈 추
Original Assignee
젠자임 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 젠자임 코포레이션 filed Critical 젠자임 코포레이션
Publication of KR20140116525A publication Critical patent/KR20140116525A/ko
Application granted granted Critical
Publication of KR102073034B1 publication Critical patent/KR102073034B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020147023225A 2012-01-20 2013-01-18 항cxcr3 항체 Expired - Fee Related KR102073034B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261588936P 2012-01-20 2012-01-20
US61/588,936 2012-01-20
PCT/US2013/022280 WO2013109974A2 (en) 2012-01-20 2013-01-18 Anti-cxcr3 antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020207002561A Division KR20200014441A (ko) 2012-01-20 2013-01-18 항cxcr3 항체

Publications (2)

Publication Number Publication Date
KR20140116525A KR20140116525A (ko) 2014-10-02
KR102073034B1 true KR102073034B1 (ko) 2020-02-05

Family

ID=47633576

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020147023225A Expired - Fee Related KR102073034B1 (ko) 2012-01-20 2013-01-18 항cxcr3 항체
KR1020207002561A Ceased KR20200014441A (ko) 2012-01-20 2013-01-18 항cxcr3 항체

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020207002561A Ceased KR20200014441A (ko) 2012-01-20 2013-01-18 항cxcr3 항체

Country Status (26)

Country Link
US (4) US8865870B2 (https=)
EP (1) EP2804878B1 (https=)
JP (3) JP6352812B6 (https=)
KR (2) KR102073034B1 (https=)
CN (1) CN104507967B (https=)
AR (1) AR090056A1 (https=)
AU (1) AU2013209492B2 (https=)
BR (1) BR112014017814A8 (https=)
CA (1) CA2862222A1 (https=)
CY (1) CY1121335T1 (https=)
DK (1) DK2804878T3 (https=)
ES (1) ES2698606T3 (https=)
HR (1) HRP20181874T1 (https=)
HU (1) HUE041900T2 (https=)
IL (2) IL233694A0 (https=)
LT (1) LT2804878T (https=)
MX (1) MX359854B (https=)
PL (1) PL2804878T3 (https=)
PT (1) PT2804878T (https=)
RS (1) RS58141B1 (https=)
RU (1) RU2663141C2 (https=)
SG (2) SG10201700735PA (https=)
SI (1) SI2804878T1 (https=)
TW (1) TWI596112B (https=)
UY (1) UY34582A (https=)
WO (1) WO2013109974A2 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
WO2016028523A2 (en) 2014-08-22 2016-02-25 Sorrento Therapeutics, Inc. Antigen binding proteins that bind cxcr3
CA3003458A1 (en) 2015-10-29 2017-05-04 Alector Llc Anti-siglec-9 antibodies and methods of use thereof
EP3464349A4 (en) * 2016-05-23 2020-08-26 New York University COMPOSITIONS AND METHODS ASSOCIATED WITH ANTIBODIES TARGETING STAPHYLOCCAL LEUCOTOXINS
EP3559036A1 (en) * 2016-12-22 2019-10-30 Sanofi Anti-human cxcr3 antibodies for treatment of vitiligo
KR20190095943A (ko) * 2016-12-22 2019-08-16 사노피 고갈 활성을 갖는 인간화 cxcr3 항체 및 이의 사용 방법
TW201840585A (zh) 2016-12-22 2018-11-16 法商賽諾菲公司 用於白斑病的治療的抗人cxcr3抗體
WO2019158675A1 (en) * 2018-02-16 2019-08-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating vitiligo
KR102074798B1 (ko) * 2018-06-15 2020-02-07 코아스템(주) 자가면역질환 치료에 대한 유효성 예측용 바이오마커, 진단키트 및 치료용 용도
EP3880239A4 (en) 2018-11-14 2022-11-23 Arch Oncology, Inc. THERAPEUTIC SIRPalpha ANTIBODIES
SG11202110145SA (en) 2020-02-26 2021-10-28 Vir Biotechnology Inc Antibodies against sars-cov-2 and methods of using the same
CN116234572A (zh) * 2020-04-30 2023-06-06 安驰肿瘤公司 治疗性SIRPα抗体
US20240101673A1 (en) 2021-02-03 2024-03-28 Mozart Therapeutics, Inc. Binding agents and methods of using the same
JP2024508304A (ja) * 2021-03-02 2024-02-26 ノヴァロック バイオセラピューティクス， リミテッド Ｃｌａｕｄｉｎ－６に対する抗体およびそれの使用
EP4384218A4 (en) * 2021-08-09 2025-11-05 Merck Patent Gmbh Proteins that uncouple T-lymphocyte-mediated tumor cytotoxicity from the release of pro-inflammatory cytokines
WO2023076876A1 (en) 2021-10-26 2023-05-04 Mozart Therapeutics, Inc. Modulation of immune responses to viral vectors
CN120112292A (zh) 2022-09-09 2025-06-06 爱杜西亚药品有限公司 包含抗-cd3抗体及cxcr3拮抗剂的药物组合
WO2025185738A1 (zh) * 2024-03-08 2025-09-12 演生潮(北京)生物科技有限公司 靶向cxcr3的抗原结合蛋白及其应用
WO2026069312A1 (en) 2024-09-24 2026-04-02 Yeda Research And Development Co. Ltd. Immune cells expressing an inducible therapeutic agent and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184358B1 (en) 1996-09-10 2001-02-06 Millennium Pharmaceuticals, Inc. IP-10/Mig receptor designated CXCR3, antibodies, nucleic acids, and methods of use therefor

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US565332A (en) 1896-08-04 Toy for making soap-bubbles
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB2183661B (en) 1985-03-30 1989-06-28 Marc Ballivet Method for obtaining dna, rna, peptides, polypeptides or proteins by means of a dna recombinant technique
US6492107B1 (en) 1986-11-20 2002-12-10 Stuart Kauffman Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
EP1291360A1 (en) 1991-12-13 2003-03-12 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
AU701578B2 (en) 1992-08-21 1999-02-04 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
WO1994025591A1 (en) 1993-04-29 1994-11-10 Unilever N.V. PRODUCTION OF ANTIBODIES OR (FUNCTIONALIZED) FRAGMENTS THEREOF DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF $i(CAMELIDAE)
JP2826272B2 (ja) 1993-10-26 1998-11-18 タイガースポリマー株式会社 中空樹脂成形品の製造装置及び製造方法
US5565352A (en) 1993-11-24 1996-10-15 Arch Development Corporation Deubiquitinating enzyme: compositions and methods
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
EP0925358B1 (en) * 1996-09-10 2007-04-25 Theodor-Kocher Institute Cxcr3 chemokine receptor, antibodies, nucleic acids, and methods of use
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
WO2001072334A2 (en) * 2000-03-27 2001-10-04 Corixa Corporation Methods for treating disease with antibodies to cxcr3
CA2464690A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of apolipoprotein d
MXPA06000252A (es) * 2003-06-30 2006-12-15 Bio Technology General Israel Anticuerpos y usos de los mismos.
WO2005030793A2 (en) * 2003-09-24 2005-04-07 Millennium Pharmaceuticals, Inc. Antibodies which bind human cxcr3
ATE557042T1 (de) * 2004-03-23 2012-05-15 Lilly Co Eli Anti-myostatin-antikörper
BRPI0514259A (pt) 2004-08-11 2008-06-03 Trubion Pharmaceuticals Inc proteìna de fusão de domìnio de ligação
BRPI0710011A2 (pt) 2006-04-14 2011-08-02 Trubion Pharmaceuticals Inc proteìnas de ligação compreendendo articulação de imunoglobulina e regiões fc dotadas de funções efetoras fc alteradas
US8435522B2 (en) * 2007-02-01 2013-05-07 Teva Biopharmaceuticals Usa, Inc. Humanized antibodies against CXCR3
CN111909273B (zh) 2007-08-29 2024-03-26 塞诺菲-安万特股份有限公司 人源化的抗-cxcr5抗体、其衍生物及它们的应用
US20100130476A1 (en) 2008-11-12 2010-05-27 The Scripps Research Institute Compounds that induce pancreatic beta-cell expansion
WO2010103517A1 (en) 2009-03-12 2010-09-16 Rappaport Family Institute For Research In The Medical Sciences Soluble compositions for the treatment of cxcr3-ligand associated diseases
CA2789963C (en) * 2010-02-26 2019-09-03 Bioarctic Neuroscience Ab Protofibril-binding antibodies and their use in therapeutic and diagnostic methods for parkinson's disease, dementia with lewy bodies and other alpha-synucleinopathies

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184358B1 (en) 1996-09-10 2001-02-06 Millennium Pharmaceuticals, Inc. IP-10/Mig receptor designated CXCR3, antibodies, nucleic acids, and methods of use therefor

Also Published As

Publication number Publication date
IL271697A (en) 2020-02-27
AU2013209492A1 (en) 2014-08-14
US8865870B2 (en) 2014-10-21
US9765144B2 (en) 2017-09-19
SI2804878T1 (sl) 2018-12-31
EP2804878A2 (en) 2014-11-26
HRP20181874T1 (hr) 2019-01-11
HUE041900T2 (hu) 2019-06-28
PL2804878T3 (pl) 2019-03-29
US20140377806A1 (en) 2014-12-25
JP6352812B2 (ja) 2018-07-04
CA2862222A1 (en) 2013-07-25
MX359854B (es) 2018-10-12
CN104507967A (zh) 2015-04-08
US20130251733A1 (en) 2013-09-26
TWI596112B (zh) 2017-08-21
CY1121335T1 (el) 2020-05-29
JP2015506945A (ja) 2015-03-05
JP6352812B6 (ja) 2018-08-08
TW201335188A (zh) 2013-09-01
UY34582A (es) 2013-09-02
RS58141B1 (sr) 2019-02-28
HK1208684A1 (en) 2016-03-11
PT2804878T (pt) 2018-11-29
SG10201700735PA (en) 2017-02-27
LT2804878T (lt) 2018-12-10
DK2804878T3 (en) 2018-12-17
IL233694A0 (en) 2014-09-30
AR090056A1 (es) 2014-10-15
AU2013209492B2 (en) 2018-02-08
JP2020072715A (ja) 2020-05-14
KR20200014441A (ko) 2020-02-10
BR112014017814A8 (pt) 2017-07-11
KR20140116525A (ko) 2014-10-02
RU2663141C2 (ru) 2018-08-01
JP2018166506A (ja) 2018-11-01
BR112014017814A2 (https=) 2017-06-20
RU2014134043A (ru) 2016-03-20
EP2804878B1 (en) 2018-08-22
MX2014008728A (es) 2015-07-06
JP6646100B2 (ja) 2020-02-14
SG11201406762QA (en) 2014-11-27
ES2698606T3 (es) 2019-02-05
US20180086838A1 (en) 2018-03-29
WO2013109974A3 (en) 2013-11-07
CN104507967B (zh) 2018-10-12
WO2013109974A2 (en) 2013-07-25
US20190119391A1 (en) 2019-04-25

Similar Documents

Publication Publication Date Title
KR102073034B1 (ko) 항cxcr3 항체
US20220289844A1 (en) Anti-SIRPa Antibodies and Methods of Use Thereof
KR102742528B1 (ko) 항-bcma 중쇄-단독 항체
TWI564305B (zh) 治療性抗體
JP2021184731A (ja) Ｃｄ１２７に対する抗体
CN106794129B (zh) 对il-21具有特异性的结合分子及其用途
KR20200061320A (ko) 세포독성 t-림프구-관련 단백질 4 (ctla-4)에 대한 신규의 단일클론 항체
JP2010518873A (ja) アンタゴニスト抗ｏｘ４０抗体および炎症性疾患および自己免疫性疾患の処置におけるその使用
CN118146370A (zh) 仅有重链的抗bcma抗体
JP2015501639A (ja) 抗ｃｄ９８抗体およびその使用方法
KR20200104342A (ko) Cd22에 결합하는 중쇄 항체
KR20240025013A (ko) 항-ccr8 항체 및 이의 용도
CN111133007A (zh) 与胞外酶结合的重链抗体
KR20240109605A (ko) 항-인간 cd3 항체 및 이의 응용
CN115298216A (zh) 抗体或其抗原结合片段、其制备方法及医药用途
CN115348971A (zh) 抗体-药物缀合物
HK1208684B (zh) 抗cxcr3抗體

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20230130

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20230130